BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 2205825)

  • 1. [Results of BCG immunotherapy in the management of bladder tumors].
    Samodai L; Kiss L; Kolozsy Z; Dauda G; Drinóczy M; Mohácsi L
    Orv Hetil; 1990 Aug; 131(31):1697-702. PubMed ID: 2205825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results obtained by intravesical instillation of BCG in superficial bladder tumors].
    Romics I; Dietmar B; Christoph R
    Orv Hetil; 1990 Jan; 131(1):25-8. PubMed ID: 2405331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Repeated yearly BCG treatment in superficial bladder cancer].
    Somogyi L; Török A; Bors G; Drinóczy M; Horváth R
    Orv Hetil; 1989 Mar; 130(13):671-3. PubMed ID: 2726237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.
    Winters WD; Lamm DL
    Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
    Zlotta A; Drowart A; van Vooren JP; Simon J; Schulman CC; Huygen K
    Acta Urol Belg; 1994 Sep; 62(3):63-8. PubMed ID: 7976857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adjuvant BCG immunotherapy in the management of superficial bladder tumors].
    Somogyi L; Szántó A; Polyák L; Baranyay F; Drinóczy M
    Orv Hetil; 1993 Aug; 134(34):1851-6. PubMed ID: 8355975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The immunotherapy of bladder tumors and the immunoprophylaxis of disease recurrence].
    Korovin AI; Savvin VT
    Urol Nefrol (Mosk); 1996; (1):19-21. PubMed ID: 8659034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
    Steinbach F; Schuster F
    Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in the activity of natural killer cells in superficial bladder cancer during intravesical BCG therapy].
    Samodai L; Dankó K
    Orv Hetil; 1992 Sep; 133(36):2283-6, 2291-2. PubMed ID: 1408062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preventive treatment of superficial tumors of the bladder using intravesical BCG. Review].
    Patard JJ; Chopin DK
    Ann Urol (Paris); 1993; 27(1):24-30. PubMed ID: 8470876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy of superficial bladder tumors in a hospital department].
    Prekopp G; Rosdy E
    Orv Hetil; 1993 Dec; 134(50):2757-60. PubMed ID: 8265124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
    Decobert M; Larue H; Bergeron A; Harel F; Pfister C; Rousseau F; Lacombe L; Fradet Y
    J Urol; 2006 Apr; 175(4):1506-11. PubMed ID: 16516037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
    Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
    J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radical cystectomy for superficial tumors in the BCG era].
    Huguet Pérez J; Palou J; Millán Rodríguez F; Villavicencio Mavrich H; Rodríguez JV
    Arch Esp Urol; 2002; 55(1):50-6. PubMed ID: 11957752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A comparative clinical trial of UFT medication and intravesical BCG in the recurrence of superficial bladder cancer. Study Group of UFT and BCG adjuvant therapy for bladder cancer].
    Oda H; Seki N; Nabeshima S; Oda T; Nishio S; Yokoyama M; Iwata H; Takeuchi M; Matsumoto A; Terado T
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):2051-5. PubMed ID: 2221929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of superficial bladder cancer.
    Morales A
    Can Med Assoc J; 1980 May; 122(10):1133-8. PubMed ID: 6770987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.